Emyria commences US preclinical program for MDMA library
Filed with ASX · · 5 pages · English
Emyria has engaged PsychoGenics, a leader in Artificial Intelligence (AI) enabled drug discovery and preclinical contract research services in neuroscience to help advance its MDMA-inspired New Drug Discovery program PsychoGenics will use its proprietary SmartCube(™) platformto study novel compounds from Emyria’s MDMA-inspired drug discovery program developed with partner the University of Western
Story so far
Earlier from Emyria
- Appendix 4E and Annual Report
- Positive results received for Emyrias MDMA-inspired program
- Emyria receives ethics approval for EMD-RX5 Phase 3 trial
- Preclinical studies initiated for MDMA-inspired analogues
- Appendix 4C - Quarterly
Later from Emyria
- Emyria expands clinical sites for EMD-RX5 Phase 3 trial
- Emyria and UWA expand unique MDMA-inspired analogue library
- Emyria completes $3m placement
- Placement completion and secondary trading notice
- Emyria accepted into National Institutes of Health Program
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria